marcos maldaun retweeted
MethyLYZR, an epigenetic classifier of brain tumors, provides clinically relevant cancer classification results within 15 minutes of sequencing, with potential applications for neurosurgical intraoperative use
nature.com/articles/s41591-0…
marcos maldaun retweeted
An article discussing development and validation of a molecular classifier of meningiomas is now available in Neuro-Oncology. 👉 academic.oup.com/neuro-oncol… #EANOessentials #NeuroOncology #Meningioma
marcos maldaun retweeted
Exciting News! Vorasidenib (brand name: Voranigo) has just been approved by the FDA for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation. Read more: braintumor.org/news/exciting…
marcos maldaun retweeted
Refinement of prognostication for IDH-mutant #astrocytomas using DNA methylation-based classification
#neuropath #braintumor
onlinelibrary.wiley.com/doi/…

ALT Overall survival (OS) probabilities of 336 patients with IDH-mutant astrocytomas in the final combined cohort stratified by (A) histological grade, (B) CDKN2A/B copy number status, (C) WHO 2021 CNS grading criteria and (D) DNA methylation-based subclassification. Significance: p < 0.05. Homo del, homozygous deletion; MC, methylation class.
The largest Neuro-oncology meeting in Latam is coming...amazing international and national speakers
Most relevent subjects in NO field covered
snola2024.com
marcos maldaun retweeted
The INDIGO trial: Precision medicine finally comes to glioma
doi.org/10.1093/neuonc/noad1…
marcos maldaun retweeted
Glioma growth involving language-eloquent centers in the brain may alter language networks. In their study, Chang et al. found various patient and radiographic characteristics in glioma patients to be associated with preoperative language performance. link.springer.com/article/10…
marcos maldaun retweeted
Is there a role for liquid biopsies in CSF in treating CNS metastases from breast cancer? Check out this recent study in #JNO to learn about how genetic alterations can be identified in CSF samples to guide targetable treatment for these patients. link.springer.com/article/10…
marcos maldaun retweeted
Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification.
academic.oup.com/neuro-oncol…
#btsm @NeuroOnc
marcos maldaun retweeted
One out of three patients with gliomas suffer from medically refractory epilepsy. Our paper discusses how IDH-mutant gliomas promote neuronal excitability through D-2-HG mediated mTOR hyperactivation, a potential therapeutic target for these patients. academic.oup.com/neuro-oncol…
marcos maldaun retweeted
#EGFR, the Lazarus target for precision oncology in #glioblastoma.
academic.oup.com/neuro-oncol…
#btsm @NeuroOnc
marcos maldaun retweeted
New! Intraoperative Monitoring provides cutting-edge information in the field of IOM, and highlights new neurophysiological tools being used in various surgeries.
#anatomicaloverview #electricalsafety, #neurophysiologicaltests
link.springer.com/book/10.10…
marcos maldaun retweeted
Great opportunities in this indications! 🦾🦾@EANOassociation @NeuroOnc @SNOLAsociety hope in LATAM got a quick approbation as well!
marcos maldaun retweeted
Everyone in contact with a brain tumor knows that this experience involves challenges, pain and hope.
In this Grey May, let's reflect on all the efforts that still need to be made to increase development in education, research and patient support.
#greymay #braintumorawareness
Let’s run and help the Hospital Clínicas da Unicamp to improve the technological park and patient assistance #run #HCRUN #runforwealthy #runforlife
A Associação Amigos do HC em
HC RUN 2022, fomentando a prática esportiva, a saúde e a mobilização social em prol do Hospital de Clínicas da Unicamp!
Saiba mais e inscreva-se já! Vagas limitadas : fef.unicamp.br/fef/corridahc…
1
1
marcos maldaun retweeted
Perspectives – Spotlight debate: Should #radiotherapy be considered for the initial treatment of #brain #metastases?
Read two sides of debate from Giuseppe Minniti and
Emilie Le Rhun: thelancet.com/journals/lanon…





















